Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julius Strauss

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Journal for Immunotherapy of Cancer|February 22, 2020
Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advancesHanne Lind, Sofia R Gameiro, Caroline Jochems, et al.
International Immunopharmacology|May 26, 2023
Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12Nicole J Toney, Margaret E Gatti-Mays, Nicholas P Tschernia, et al.
Journal for Immunotherapy of Cancer|April 14, 2022
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfaYo-Ting Tsai, Julius Strauss, Nicole J Toney, et al.
Expert Review of Anticancer Therapy|August 27, 2014
Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNARuth A Bryan, Zewei Jiang, Thomas Jandl, et al.
Journal for Immunotherapy of Cancer|July 6, 2022
Non-synergy of PD-1 blockade with T-cell therapy in solid tumorsJohn S Davies, Farrah Karimipour, Ling Zhang, et al.
Journal of Gastrointestinal Oncology|October 12, 2019
Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vasospasm during first 5-FU infusionJason M Redman, Logan P Rhea, Alessandra Brofferio, et al.
Frontiers in Immunology|March 19, 2025
Case Report: The immune architecture of immunotherapy-induced cutaneous sarcoidosis resembles peritumoral inflammationCatherine J Wang, Jennifer Strong, Margaret E Gatti-Mays, et al.
The Oncologist|June 13, 2023
Avelumab in Patients With Metastatic Colorectal CancerJason M Redman, Geraldine O'Sullivan Coyne, Clay T Reed, et al.
Journal for Immunotherapy of Cancer|May 5, 2019
Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosisClint T Allen, Sunmin Lee, Scott M Norberg, et al.
Journal for Immunotherapy of Cancer|November 7, 2023
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancerThomas A Odeny, Kathryn Lurain, Julius Strauss, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Journal for Immunotherapy of Cancer|February 22, 2020
Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advancesHanne Lind, Sofia R Gameiro, Caroline Jochems, et al.
International Immunopharmacology|May 26, 2023
Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12Nicole J Toney, Margaret E Gatti-Mays, Nicholas P Tschernia, et al.
Journal for Immunotherapy of Cancer|April 14, 2022
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfaYo-Ting Tsai, Julius Strauss, Nicole J Toney, et al.
Expert Review of Anticancer Therapy|August 27, 2014
Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNARuth A Bryan, Zewei Jiang, Thomas Jandl, et al.
Journal for Immunotherapy of Cancer|July 6, 2022
Non-synergy of PD-1 blockade with T-cell therapy in solid tumorsJohn S Davies, Farrah Karimipour, Ling Zhang, et al.
Journal of Gastrointestinal Oncology|October 12, 2019
Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vasospasm during first 5-FU infusionJason M Redman, Logan P Rhea, Alessandra Brofferio, et al.
Frontiers in Immunology|March 19, 2025
Case Report: The immune architecture of immunotherapy-induced cutaneous sarcoidosis resembles peritumoral inflammationCatherine J Wang, Jennifer Strong, Margaret E Gatti-Mays, et al.
The Oncologist|June 13, 2023
Avelumab in Patients With Metastatic Colorectal CancerJason M Redman, Geraldine O'Sullivan Coyne, Clay T Reed, et al.
Journal for Immunotherapy of Cancer|May 5, 2019
Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosisClint T Allen, Sunmin Lee, Scott M Norberg, et al.
Journal for Immunotherapy of Cancer|November 7, 2023
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancerThomas A Odeny, Kathryn Lurain, Julius Strauss, et al.
Pageof 4